Becker's Healthcare June 25, 2024
Ashleigh Hollowell

Vutrisiran, a new drug made by Alnylam Pharmaceuticals to treat ATTR amyloidosis with cardiomyopathy, reduced the risk of death by 36% in patients, the drugmaker announced June 24.

Overall, in phase 3 trials, vutrisiran caused almost no adverse events in patients.

“[V]utrisiran has the potential to address the needs of patients with ATTR amyloidosis with cardiomyopathy, a steadily progressive, debilitating, and ultimately fatal disease,” Pushkal Garg, MD, chief medical officer of Alnylam, said in a news release. “The results showed that vutrisiran improved cardiovascular outcomes, including survival, function and...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Related Articles:
Walgreens to reduce stake in VillageMD
Drug prices have risen almost 40% over the past decade, according to a new tracker
Walgreens stock plunges as drugstore chain slashes profit guidance in 'challenging' consumer environment
Walgreens Considers Closing 25% of Stores Amid Consumer Price Sensitivity
All 71 CHS hospitals to use Mark Cuban's drug wholesale services

Share This Article